S&P 500   4,482.73
DOW   34,715.39
QQQ   361.72
S&P 500   4,482.73
DOW   34,715.39
QQQ   361.72
S&P 500   4,482.73
DOW   34,715.39
QQQ   361.72
S&P 500   4,482.73
DOW   34,715.39
QQQ   361.72

Bausch Health Companies Stock Forecast, Price & News

-0.66 (-2.58%)
(As of 01/20/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
5.12 million shs
Average Volume
5.03 million shs
Market Capitalization
$8.94 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive BHC News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch Health Companies and its competitors with MarketBeat's FREE daily newsletter.

Bausch Health Companies logo

About Bausch Health Companies

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.


Bausch + Lomb to Return to Public Markets
January 14, 2022 |  finance.yahoo.com
BHC March 4th Options Begin Trading
January 13, 2022 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Year Founded

Sales & Book Value

Annual Sales
$8.03 billion
Cash Flow
$8.74 per share
Book Value
$1.70 per share


Net Income
$-560 million
Pretax Margin




Free Float
Market Cap
$8.94 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.83 out of 5 stars

Medical Sector

36th out of 1,418 stocks

Pharmaceutical Preparations Industry

8th out of 683 stocks

Analyst Opinion: 3.2Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 2.5 5 -4 -3 -2 -1 -

Bausch Health Companies (NYSE:BHC) Frequently Asked Questions

Is Bausch Health Companies a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last year. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Bausch Health Companies stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BHC, but not buy additional shares or sell existing shares.
View analyst ratings for Bausch Health Companies
or view top-rated stocks.

How has Bausch Health Companies' stock price been impacted by COVID-19 (Coronavirus)?

Bausch Health Companies' stock was trading at $18.45 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BHC stock has increased by 35.1% and is now trading at $24.92.
View which stocks have been most impacted by COVID-19

When is Bausch Health Companies' next earnings date?

Bausch Health Companies is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Bausch Health Companies

How were Bausch Health Companies' earnings last quarter?

Bausch Health Companies Inc. (NYSE:BHC) issued its earnings results on Tuesday, November, 2nd. The company reported $1.14 EPS for the quarter, topping the Zacks' consensus estimate of $1.07 by $0.07. The business had revenue of $2.11 billion for the quarter, compared to analyst estimates of $2.15 billion. Bausch Health Companies had a negative net margin of 13.85% and a negative trailing twelve-month return on equity of 2,440.75%.
View Bausch Health Companies' earnings history

What guidance has Bausch Health Companies issued on next quarter's earnings?

Bausch Health Companies updated its FY 2021 earnings guidance on Tuesday, November, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $8.40 billion-$8.60 billion.

What price target have analysts set for BHC?

9 Wall Street analysts have issued 12-month price objectives for Bausch Health Companies' stock. Their forecasts range from $27.00 to $55.00. On average, they expect Bausch Health Companies' share price to reach $36.63 in the next year. This suggests a possible upside of 47.0% from the stock's current price.
View analysts' price targets for Bausch Health Companies
or view top-rated stocks among Wall Street analysts.

Who are Bausch Health Companies' key executives?

Bausch Health Companies' management team includes the following people:
  • Joseph C. Papa, Chairman & Chief Executive Officer
  • Thomas J. Appio, President & Co-Head-Bausch Lomb International
  • Sam Eldessouky, CFO, Chief Accounting Officer, SVP & Controller (LinkedIn Profile)
  • Tage Ramakrishna, Chief Medical Officer, President-R&D
  • Christina M. Ackermann, Executive Vice President & General Counsel

What is Joseph C. Papa's approval rating as Bausch Health Companies' CEO?

43 employees have rated Bausch Health Companies CEO Joseph C. Papa on Glassdoor.com. Joseph C. Papa has an approval rating of 97% among Bausch Health Companies' employees. This puts Joseph C. Papa in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Bausch Health Companies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bausch Health Companies investors own include Gilead Sciences (GILD), Micron Technology (MU), Constellation Software (CSU), Intact Financial (IFC), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Advanced Micro Devices (AMD) and Bank of America (BAC).

What is Bausch Health Companies' stock symbol?

Bausch Health Companies trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHC."

Who are Bausch Health Companies' major shareholders?

Bausch Health Companies' stock is owned by a number of retail and institutional investors. Top institutional investors include Clear Street LLC (1.03%), Parkside Investments LLC (0.06%), Poehling Capital Management LLC (0.03%), Armstrong Henry H Associates Inc. (0.02%), Cutler Group LP (0.00%) and Crossmark Global Holdings Inc. (0.01%). Company insiders that own Bausch Health Companies stock include Amy B Wechsler, Christina Ackermann, Eschenbach Andrew C Von, Holdings LP Valueact, John Paulson, Robert Spurr, Russell Barrans, Sam Eldessouky, Schutter Richard U De, Steven D Miller and William D Humphries.
View institutional ownership trends for Bausch Health Companies

Which major investors are selling Bausch Health Companies stock?

BHC stock was sold by a variety of institutional investors in the last quarter, including Armstrong Henry H Associates Inc., Jackson Square Capital LLC, Cohen Klingenstein LLC, and Newbridge Financial Services Group Inc.. Company insiders that have sold Bausch Health Companies company stock in the last year include Amy B Wechsler, Christina Ackermann, Robert Spurr, and Sam Eldessouky.
View insider buying and selling activity for Bausch Health Companies
or view top insider-selling stocks.

Which major investors are buying Bausch Health Companies stock?

BHC stock was acquired by a variety of institutional investors in the last quarter, including Clear Street LLC, Kestra Advisory Services LLC, Cutler Group LP, Crossmark Global Holdings Inc., Parkside Investments LLC, Spire Wealth Management, Poehling Capital Management LLC, and IFP Advisors Inc. Company insiders that have bought Bausch Health Companies stock in the last two years include Christina Ackermann, Eschenbach Andrew C Von, Holdings LP Valueact, John Paulson, Russell Barrans, Schutter Richard U De, and Steven D Miller.
View insider buying and selling activity for Bausch Health Companies
or or view top insider-buying stocks.

How do I buy shares of Bausch Health Companies?

Shares of BHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bausch Health Companies' stock price today?

One share of BHC stock can currently be purchased for approximately $24.92.

How much money does Bausch Health Companies make?

Bausch Health Companies has a market capitalization of $8.94 billion and generates $8.03 billion in revenue each year. The company earns $-560 million in net income (profit) each year or ($3.28) on an earnings per share basis.

How many employees does Bausch Health Companies have?

Bausch Health Companies employs 21,600 workers across the globe.

What is Bausch Health Companies' official website?

The official website for Bausch Health Companies is www.bauschhealth.com.

Where are Bausch Health Companies' headquarters?

Bausch Health Companies is headquartered at 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8.

How can I contact Bausch Health Companies?

Bausch Health Companies' mailing address is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. The company can be reached via phone at (514) 744-6792, via email at [email protected], or via fax at 514-744-6272.

This page was last updated on 1/21/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.